Management of Hepatocellular Carcinoma: Updated Review

Elbaz, Tamer; Kassas, Mohamed El; Esmat, Gamal

doi:10.4236/jct.2013.42067

Cited by 15 publications

(12 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatocellular carcinoma (HCC) is a challenging tumor that usually develops on top of chronic liver disease and liver cirrhosis . Generally, it has a bad prognosis so that its incidence is nearly equal to its mortality rate .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of trail receptor 1 (DR4) polymorphisms C626G and A683C as risk factors of hepatocellular carcinoma

Alsalawy

Darwish

Kamal

et al. 2017

Journal of Medical Virology

View full text Add to dashboard Cite

Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) plays an important role in many cancers including hepatocellular carcinoma (HCC). The aim of this study is to investigate the association of the DR4 polymorphisms C626G (Thr209Arg, rs20575) and A683C (Glu228Ala, rs20576) with the occurrence of HCC in Egyptian patients chronically infected with HCV. The study included 80 patients with HCV-related HCC (group 1) and 80 patients with HCV-related liver cirrhosis (group 2) who are naïve to treatment. Clinical and laboratory data were recorded. Genotyping of TRAIL receptor DR4 polymorphism C626G rs20575 and A683C rs20576 SNP was done by Real-Time PCR using taqman probes technology. The mean age of HCC patients was 57.6 ± 8.4 years with 62 patients (77.5%) were males. While group 2 mean age was 49.5 ± 10.29 years with 50% were males. The frequency distribution of rs20575 genotypes showed a statistically significant difference between the two studied groups (P = 0.02), the carriers of the C allele were 2.01 times more likely to develop HCC than the carriers of the G allele (P = 0.003), while no significant difference in rs20576 genotypes distribution was found between the studied groups (P = 0.680). On combining the carriers of C allele of rs20575 and the carriers of A allele of rs20576, a significant difference was detected (P > 0.001) with 2.85 higher risk of HCC development in patients who carried both genetic risk alleles simultaneously. The significant difference in DR4 polymorphisms among HCC and cirrhotic patients suggests their role as potential risk factors of HCC development.

show abstract

Section: Introductionmentioning

confidence: 99%

Evaluation of trail receptor 1 (DR4) polymorphisms C626G and A683C as risk factors of hepatocellular carcinoma

Alsalawy

Darwish

Kamal

et al. 2017

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…In most institutions TACE is considered as an option when the patient is not a surgical candidate for the treatment of hepatocellular carcinoma (HCC) [2][3][4][5][6][7] . It is indicated as a palliative treatment and considered as the first line therapy for intermediate stage hcc according to the recommendation of american association for study of liver diseases based on randomized controlled trials 8 . TACE is simply administration of cytotoxic drugs with or without lipiodol, by means of a catheter positioned in the tumor supplying hepatic artery followed by the administration of embolizing agents such as spherical gelatin or polyvinyl alcohol particles 9 .…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Intra-Arterial Lidocaine for Pain Control Resulting From Transarterial Chemoembolization of Hepatocellular Carcinoma

Abbas

Sheraz

Rahim

2021

PAFMJ

View full text Add to dashboard Cite

Objective: To assess the efficacy of intra-arterial lidocaine in peri & post-procedural pain control and the dose of narcotic analgesic required in hepatocellular carcinoma patients undergoing transarterial chemoembolization. Study Design: Comparative prospective study. Place and Duration of Study: Armed Forces Institute of Radiology and Imaging Rawalpindi, from Jan to Jun 2019. Methodology: A total of 60 patients included in this study where 42 males and 18 were females, age range 45-85 years who underwent transarterial chemoembolization for hepatocellular carcinoma, were included in the study. patients were equally divided into two groups, group a (30 patients) who underwent transarterial chemoembolization, received 60 mg of intraarterial lidocaine each and group b (30 patients) who underwent transarterial chemoembolization, intra-arterial lidocaine was substituted with normal saline.degree of post-procedural pain was assessed using a subjective method (visual analogue scales score) and an objective method (amount of post-procedural analgesics). Results: Average peri-procedure visual analogue scale score was 5.06 in group A patient versus 7.2 for those in group B patients (p=0.037). Post-procedure visual analogue scale score in the group A was 2.7 ± 0.520 and that for group B was 4.2 ± 0.761 (p=0.025). Mean of total dose of nalbuphine in group A was 4.96 ± 0.764 mg versus 8.3 ± 1.34 mg for patients in group B (p=0.036). Average length of post procedure hospital stay was 0.9 ± 0.203 and 1.41 ± 0.373 days for group A and group B respectively (p=0.002).Conclusion: Intra-arterial administration of lidocaine before infusing the embolization particles for transarterial chemoembolization.....................

show abstract

“…The recent advances in the different therapeutic approaches of hepatocellular carcinoma (HCC), including percutaneous radiofrequency ablation (RFA) and microwave ablation (MWA), had led to a real change in its unpromising picture (1)(2)(3). MWA was demonstrated in different reports to have equivalent efficacy, safety, and survival rates with shorter procedure time than RFA for HCC management, especially lesions that are nearby vessels (4,5).…”

Section: Introductionmentioning

confidence: 99%

Percutaneous microwave ablation for HCV-related hepatocellular carcinoma: Efficacy, safety, and survival

Darweesh

Gad

2019

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: Hepatocellular carcinoma (HCC) has a poor prognosis if managed late. Percutaneous microwave ablation (MWA) emerged as one of the top therapeutic decisions for non-surgical patients. The aim of the present study aim was to evaluate the efficacy, side effects, and survival after MWA of hepatitis C virus (HCV)-related HCC tumors with spectrum sizes up to 5 cm. Materials and Methods: Fifty-nine patients with early HCC were treated in the Hepatology Department using percutaneous MWA. Patients were assessed for side effects and efficacy that includes the rate of complete ablation, primary or de novo recurrence, and survival. Results: Complete ablation was achieved in 57 (96.6%) patients treated by MWA, with a minor complication rate of 3.3% (n=2) including liver abscess formation and abdominal skin burn. The ablation rates in lesions <3 versus 3-5 cm were not different. Of the patients, 3 (5%) had primary recurrence in the treated HCC tumors, de novo lesions (secondary recurrence) developed in 8 (13.5%, 5 of them >3 cm), and 2 (3.3%) had malignant portal vein thrombosis. The survival rates were 95.4% and 69% at 1 and 2 years, respectively. Conclusion: Percutaneous MWA had achieved a safe and effective treatment with good overall survival in patients with HCV-related HCC.

show abstract

Management of Hepatocellular Carcinoma: Updated Review

Cited by 15 publications

References 84 publications

Evaluation of trail receptor 1 (DR4) polymorphisms C626G and A683C as risk factors of hepatocellular carcinoma

Evaluation of trail receptor 1 (DR4) polymorphisms C626G and A683C as risk factors of hepatocellular carcinoma

Efficacy of Intra-Arterial Lidocaine for Pain Control Resulting From Transarterial Chemoembolization of Hepatocellular Carcinoma

Percutaneous microwave ablation for HCV-related hepatocellular carcinoma: Efficacy, safety, and survival

Contact Info

Product

Resources

About